drugset / Trial / NCT07520214
Clinical Study on the Safety and Immunogenicity of Specific Cancer Vaccines in Preventing Recurrence of Glioblastoma
Non-randomizedSequentialOpen-labelTreatment
Summary
This study evaluates the safety and specific antitumor immune responses of mRNA vaccines GV-108 and GV-907 in IDH-wildtype glioblastoma patients.
Timeline
- Start
- 2025-09-10
- Primary completion
- 2027-12-31
- Completion
- 2027-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GV-108 | Messenger RNA (mRNA) | 100 ug | Other |
| Subject | GV-108 | Messenger RNA (mRNA) | 150 ug | Other |
| Subject | GV-108 | Messenger RNA (mRNA) | 200 ug | Other |
| Subject | GV-907 | Messenger RNA (mRNA) | 100 ug | Other |
| Subject | GV-907 | Messenger RNA (mRNA) | 150 ug | Other |
| Subject | GV-907 | Messenger RNA (mRNA) | 200 ug | Other |